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ABSTRACT 
Obiective: To determine the efficacy and safety of intravitreal 
injection of ganciclovir for active cytomegalovirus (CMV) retini- 
tis in AIDS patients who are intolerant of systemic ganciclovir 
therapy. 
Methods: An open-labeled trial of intravitreal ganciclovir induc- 
tion and maintenance therapy was conducted in outpatient 
clinics of five AIDS Clinical Trials Units. Sixteen eyes of 11 
patients were treated; 11 eyes of eight patients were included 
in the analysis. Patients were treated with a series of two 
intravitreal injections per week for the first 3 weeks (induction 
period), followed by one injection per week until an endpoint 
was reached or for a total of 24 weeks. Each injection con- 
tained 200 ug ganciclovir in a total volume of 0.1 mL, adminis- 
tered through a 30-gauge needle. The primary endpoint 
measures were the time to retinitis progression as evidenced 
by the development of a new lesion or progression by more 
than 750 pm of a preexisting lesion, and progression of CMV 
as evidenced by development of active disease in the 
untreated eye or at an extraocular site. Other outcome mea- 
sures were changes in visual acuity and adverse events related 
to the intravitreal injections. 
Results: All of the treated eyes responded to induction therapy, 
and three eyes were successfully reinduced a total of four times. 
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Median time to retinitis progression was 8.9 weeks (range, 
6-20 wk). Cytomegalovirus disease of the untreated fellow eye 
or at an extraocular site occurred in four of seven patients 
(57%) for whom adequate follow-up data exist, at a mean of 
11.7 weeks of study. lntravitreal injections were well-tolerated, 
and all complications were transient and reversible. 
Conclusions: lntravitreal ganciclovir therapy is effective for the 
treatment of active CMV retinitis, with median times to retinitis 
progression comparable to those achieved with systemic ther- 
apy, and may be administered with minimal complications. 
However, the frequent occurrence of CMV disease in the 
untreated fellow eye and at extraocular sites suggests that 
when used as sole therapy, intravitreal treatment should be 
given for short periods of time, when systemic therapy is not 
possible. 
Key Words: cytomegalovirus, eye, ganciclovil; intravitreal 
injection, retinitis 
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Cytomegalovirus (CMV) retinitis is the most frequent oph- 
thalmic opportunistic infection seen in patients with 
acquired immunodeficiency syndrome (AIDS). The risk of 
developing CMV retinitis increases the longer the CD4 
lymphocyte count is below 50/mm3, with a median time 
to diagnosis of 13 months.‘x2 After 2 years of observation, 
over 40% of such patients will have developed retinitis.’ 
Intravenously administered ganciclovir and foscarnet 
are effective therapies and are approved for CMV retini- 
tis in AIDS patients - 3 15; however, chronic administration 
is required in order to prevent reactivation of disease, 
and breakthroughs are common. Intravenous ganciclovir 
therapy is commonly complicated by neutropenia, which 
may be dose-limiting, requiring suspension or discontin- 
uation of therapy.3-9 Foscarnet is nephrotoxic and has 
been associated with mineral and electrolyte imbal- 
ances.1°-15 Although withholding ganciclovir typically 
allows for recovery of the granulocyte count, such dis- 
continuous therapy may allow intervening reactivation 
of the retinitis and further retinal destruction. Prior to 
the availability of hematopoietic growth factors such as 
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granulocyte- or granulocyte/macrophage-colony stimu- 
lating factors (G-CSF, GM-CSF), discontinuous ganciclovir 
therapy occurred regularly and probably contributed to 
early retinitis progression. 
Since the original report of Hem-y and colleagues in 
1987,16 establishing the technique of intermittent intra- 
vitreal ganciclovir injection, several small case series of 
the use of such therapy have been reported.“-19 In gen- 
eral, these studies have demonstrated effective suppres- 
sion of retinitis for several weeks, usually until the 
neutropenia resolves. Heinemann has reported that such 
therapy is safe and effective over as long as 56 weeks.20 
This report presents results of a multicenter trial of 
open-labeled intravitreal ganciclovir salvage therapy in 
patients with active CMV retinitis who are intolerant of 
systemic ganciclovir therapy. As neither foscarnet nor 
G-CSF were approved when this study was designed, this 
study represented one of the investigational salvage 
options available to patients at the time. 
SUBJECTS AND METHODS 
Patients were eligible if they met the 1987 CDC surveil- 
lance definition for AIDS and had active CMV retinitis, 
in one or both eyes, despite previous systemic ganciclo- 
vir therapy They either had to have experienced dose- 
limiting toxicity or must have been unable to initiate 
systemic ganciclovir due to neutropenia (absolute neu- 
trophil count of less than 750/mm3). The diagnosis of 
CMV retinitis was made by indirect ophthalmoscopy and 
documented by fundus photography. Exclusion criteria 
included concurrent treatment with systemic ganciclovir 
or foscarnet, CMV hyperimmune globulin, G- or GM-CSF; 
thrombocytopenia (platelet count <25,000/mm3); obvious 
external ocular infection; and ocular media opacities that 
might preclude adequate visualization of the retina and 
optic nerve. 
As the study was originally conceived, patients’ eyes 
with non-sight-threatening retinitis (lesions >3000 pm 
from the fovea and/or 1500 microns from the optic disk) 
were to be randomized independently to either immedi- 
ate or deferred therapy, with therapy instituted when 
progression was demonstrated. Eyes with sight-threaten- 
ing retinitis (lesions within 3000 pm of the fovea and/or 
1500 microns from the optic disk) were treated imme- 
diately. Patients with bilateral sight-threatening retinitis 
and salvageable vision for whom appropriate systemic 
therapy was not available were allowed to receive con- 
current bilateral intravitreal therapy at the discretion of 
their physician. Bilateral therapy was also allowed if CMV 
retinitis occurred or progression was demonstrated in 
the contralateral eye of patients presenting with unioc- 
ular disease. Because of poor accrual into the randomized 
portion of the study (one patient), the protocol was 
amended to eliminate randomization. 
Ganciclovir, pre-filled vials of sterile water, and nor- 
mal saline for reconstitution were supplied by Syntex 
Research (Palo Alto, CA). This protocol was approved by 
the Institutional Review Boards at each of the partici- 
pating sites. 
All patients enrolled in the trial underwent baseline 
ophthalmologic examination, which included determi- 
nation of best corrected visual acuity, using Snellen eye 
charts, slit-lamp biomicroscopy, indirect ophthalmoscopy, 
tonometry, and nine-field wide-angle fundus photogra- 
phy, Baseline fundus drawings were recorded by the 
examining ophthalmologist. Additional studies included 
complete blood count with platelet count, prothrombin 
and partial thromboplastin times, and blood chemistry 
studies. 
Follow-up ophthalmologic evaluations were per- 
formed twice weekly for the first 3 weeks and then 
weekly Fundus photography was repeated at weeks 1,3, 
and 4 and then at 4week intervals, and interpreted by the 
treating ophthalmologist in an unmasked fashion. Hema- 
tologic studies were performed every 2 weeks, and care- 
ful symptom-directed examinations for other manifest- 
ations of CMV disease were performed as indicated. 
Induction therapy for all patients included an initial 
series of six injections, 200 ug/O.l mL per treatment, 
administered twice weekly for the first 3 weeks. Subse- 
quent injections were administered once weekly, for a 
total of 24 weeks of therapy. Bilateral injections were per- 
formed at the same visit. Treatment could be continued 
for an additional 24 weeks on a case-by-case basis. The 
technique of injection was modeled after that previously 
reported.16~‘sJ0 Ganciclovir was supplied as a sterile 
lyophilized powder, 500 mg per vial. This was reconsti- 
tuted with 5 mL sterile water for injection (without preser- 
vatives) to yield a 100 mg/mL solution. When thoroughly 
dissolved, 0.2 mL (20 mg) of the solution was removed 
and added to a vial of 9.8 mL sterile normal saline (with- 
out preservatives), yielding a normal saline solution con- 
taining 2 mg ganciclovir/mL. Final volume for intravitreal 
injection was 0.1 mL (200 ug ganciclovir). The drug was 
administered within 2 hours of preparation. Injections 
were performed on an outpatient basis under topical anes- 
thesia. Prior to injection, the conjunctivae and fornices 
were irrigated with sterile saline and, in some cases, povi- 
done-iodine solution. Injections were made 3.5 to 4.0 mm 
from the corneoscleral limbus in the inferotemporal quad- 
rant. A 30-gauge, one-half inch needle was used for injec- 
tion. Following injection, the patency of the central retinal 
artery was established ophthalmoscopically. Topical 
antibacterial drops were allowed the day before, the day 
of, and the day following treatment. 
Primary ophthalmologic endpoints included the pro- 
gression of retinitis, using the following criteria: develop- 
ment of a new retinal CMV lesion, advancement by 750 
km or more of the border of any preexisting CMV lesion, 
or advancement to a new sector (one or more clock hour 
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positions) of lesions posterior to the equator. Secondary 
endpoints included changes in visual acuity of two lines 
(Snellen test) or more, or qualitative changes in disease 
activity as manifested by changes in the degree of opaci- 
fication of the lesion border, and the development of 
extraocular CMV disease. Patients were eligible to remain 
on intravitreal therapy after an endpoint was reached if, 
in the opinion of the treating physicians, this was the 
best available therapy The statistical analysis includes 
simple descriptive statistics and product-limit methods 
for time-to-event estimates (medians). 
RESULTS 
Sixteen eyes of 11 patients were enrolled in this study 
from January 1990 to July 1991 at five AIDS Clinical Tri- 
als Units. Of these, three eyes (2 patients) were excluded 
from analysis because of ineligibility and two eyes (1 
patient) were excluded because the patient died of HIV- 
associated encephalopathy during induction. This analy- 
sis, therefore, concerns 11 eyes from eight patients. 
Patient demographic data are presented in Table 1. The 
patients ranged in age from 34 to 53 years (mean, 43 yr). 
All were homosexual men; six were white, and two, His- 
panic. All patients had received previous therapy with 
intravenous ganciclovir and entered the study because 
of recrudescent CMIV retinitis and neutropenia requiring 
discontinuation of systemic ganciclovir therapy. All had 
ocular symptoms that included floaters and loss of vision. 
Information concerning the course of therapy for 
each eye is presented in Table 2. Three patients had bilat- 
eral retinitis, and five had uniocular disease at entry. Ten 
of 11 eyes had sight-threatening retinitis at entry and 
received immediate treatment. Only one patient with 
bilateral disease was entered into the randomized por- 
tion of the study, with one eye treated immediately and 
the other, with non-sight-threatening disease, deferred 
until progression was documented. The eye randomized 
to deferred therapy required intravitreal ganciclovir after 
3 weeks of observation because of progression. All 
treated eyes were followed clinically for a minimum of 
4 weeks to a maximum of 3 1 weeks (mean, 12.7 wk on 
therapy, 17.8 wk on study), with receipt of 7 to 33 intra- 
vitreal injections over this period. Two patients came off 
study after completing the protocol, one dropped out 
Table 1. Patient Demographic Data 
Age Race/ Karnofsky Bilateral Sight- 
Patient (yt$ Ethnicity Score Active Retinitis Threatening 
1 45 White 50 Yes Yes/No 
2 41 White 70 Yes Yes/Yes 
3 43 White 90 No Yes 
4 34 Hispanic 90 No Yes 
5 53 Hispanic 70 No Yes 
6 53 White 70 No Yes 
7 42 White 80 Yes Yes/Yes 
8 35 White 80 No Yes 
Table 2. Course of Treatment 
Successful 
Reinduction with Total 
Number of Retinitis In travitreal Weeks on 
Patient Eye Injections Progression * Therapy Therapy 
1 A 23 20 Not Done 20 
B 17 14 Not Done 14 
2 A 9 6 Not Done 6 
B 9 6 Not Done 6 
3 A 23 8 Yes 20 
4 A 24 9 Yes 21 
5 A 7 3 Not Done 4 
6 A 14 9 Not Done 11 
7 A 7 4 Not Done 4 
B 7 4 Not Done 4 
8 A 33 10 Yes (twice) 31 
*Number of weeks on maintenance therapy. 
early in order to receive chronic twice weekly intravitreal 
injections, and five patients died while on study Of these, 
four had developed progression of CMV disease prior to 
death. Though it was likely that CMV disease played a 
role in these deaths, none could be directly attributable 
to CMV disease. 
AU of the treated eyes responded to induction ther- 
apy. Within 2 to 3 weeks of beginning therapy, retinitis 
stabilized, with decreases in the degree of retinal necro- 
sis and edema. However, this ophthalmologic response 
was not associated with a change in visual acuity from 
baseline. Retinitis progression was subsequently docu- 
mented in 8 of 11 treated eyes. For the other three eyes, 
retinitis progression could not be documented, because 
one patient (two eyes) developed extraocular disease 
(CMV pneumonitis) at the end of the induction period, 
requiring systemic ganciclovir, and another patient (one 
eye) died of Staphylococcus aureus sepsis after 4 weeks 
on study For the eight remaining eyes, the product-limit 
estimate for median time to retinitis progression was 8.9 
weeks (range for progressed eyes, 6 to 20 wk) (Figure 1). 
Three of these eyes were successfully reinduced with 
intravitreal ganciclovir a total of four times. 
Progression of CMY disease, regardless of site, was 
documented in all seven patients who survived beyond 
the third week of the study, at a median time of 8.5 weeks 
(range, 4 to 20 wk) (Figure 2). Cytomegalovirus disease 
of the fellow eye or at an extraocular site occurred in 
four of these seven patients (57%) at a mean time of 13.5 
weeks (Table 3). Gastrointestinal CMV disease developed 
in three cases (at weeks 10, 18, and 20), and pneu- 
monitis, in one (week 4). Two of the patients who 
developed gastrointestinal disease simultaneously devel- 
oped retinitis in the untreated fellow eye. All of these 
patients were treated with intravenous ganciclovir. 
Treatment was generally well tolerated and no 
patients discontinued participation because of an adverse 
event. All severe (grades 3 and 4) complications of intra- 
vitreal injection were transient and reversible (Table 4). 
There were no episodes of retinal detachment or endoph- 
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Figure 1. Time to first CMV retinitis progression (11 eyes, 3 cen- 
sored) by the product-limit method. 
thalmitis, the two most serious potential complications 
of intravitreal injection. 
DISCUSSION 
The diagnosis of CMV retinitis adds measurably to the 
morbidity associated with advanced HIV disease, not only 
due to the potential loss of vision but also because of 
the difficulty in treating this disease. The currently 
approved therapies, ganciclovir and foscarnet, although 
effective, are relatively difficult to administer and are 
often associated with dose-limiting toxicity. Both must 
be administered on a daily basis, usually via an indwelling 
central catheter. Catheter management may be difficult, 
especially for patients with decreased visual acuity and 
distorted depth perception. Nearly all such catheters will 
become infected, resulting in catheter-related bac- 
teremia.15 Dose-limiting neutropenia occurs in up to 20% 
of AIDS patients treated for CMV retinitis with intra- 
venous ganciclovir, and although currently many may be 
managed with the hematopoietic growth factors G- or 
GM-CSF, these agents were not available by prescription 
when this trial was in progress. Foscarnet therapy is fre- 
quently associated with nephrotoxicity and/or mineral 
and electrolyte disturbances. It is therefore desirable to 
have a local therapy available for those periods during 
which systemic therapy is not possible. Intravitreal ther- 
apy provides such an option. 
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Figure 2. Time to CMV disease progression at any site (11 eyes, 
1 censored) by the product-limit method. 
In this study the median time to retinitis progression 
of 8.9 weeks was similar to that in the largest study of 
systemic therapy of CMV retinitis,15 suggesting that this 
form of local therapy is effective. Although retinitis is the 
most common manifestation of CMV disease in patients 
with AIDS,’ CMV infection is generally thought of as a sys- 
temic disease with viremia that may lead to other end- 
organ involvement. It is surprising, therefore, that 
extraocular CMV is only rarely reported in the previously 
published case series of intravitreal ganciclovir ther- 
apy. l’-‘O The authors found development of CMV disease 
beyond the treated eye, occurring either as disease in 
the untreated fellow eye or at some extraocular site, to 
be an important shortcoming of intravitreal therapy: 57% 
of patients had CMV disease documented elsewhere dur- 
ing the study Intravitreal therapy was particularly well tol- 
erated in this study, with only transient and reversible 
adverse effects and a notable lack of retinal detachment 
or endophthalmitis. 
Recently, an implantable intraocular device that 
releases ganciclovir in a sustained fashion over 4 to 8 
Table 3. Development of Extraocular Disease 
Patient Site Study Week Treatment 
3 Colon, fellow eye 20 IV ganciclovir 
4 Esophagus, fellow eye 19 IV ganciclovir 
6 Colon 11 IV ganciclovir 
7 Lung 4 IV ganciclovir 
74 International Journal of Infectious Diseases / Volume 1, Number 2, November 1996 
Table 4. Severe Complications of Therapy 
Complication 
Blurring of vision 
Centrajartety closed 
Leakage of ganciclovir 
New vitreous reaction 
Posterior vitreous detachment 
Subconjunctival hemorrhage 
Temporary blackening of vision 
Transient loss of vision 
Number Number of 
of Eyes Events Reported 
3 3 
3 9 
1 1 
1 1 
1 4 
1 1 
1 1 
4 6 
months of therapy has been developed and appears to be 
effective for the treatment of CMV retinitis in AIDS 
patients.21 This sustained-release implant has the ad- 
vantage of a single surgical procedure (that may have to 
be repeated after the ganciclovir is spent) rather than 
weekly intravitreal injections, which are associated with 
adverse events ranging from mild discomfort to repeated 
deformation of the globe and violation of the vitreous 
and, in extreme cases, sight-threatening endophthalmitis 
and retinal detachment. As was the case in the present 
study, disease in the fellow eye (67%) and at extraocular 
sites (3 1%) was observed frequently when the implant 
was used as sole therapy for retinitis.*l Others have 
attempted intravitreal injections of up to 2 mg ganciclovir 
per 0.1 mL with good results.22 
This study demonstrates that although local therapy 
delivered by intravitreal injection is effective at control- 
ling retinitis, disease in the untreated fellow eye and at 
extraocular sites occurs regularly and is a serious limita- 
tion. Results suggest that intravitreal therapy, as the sole 
treatment for CMV retinitis, is most suitable only for short 
periods, when systemic therapy is not possible. 
Although the treatment options available to patients 
with CMV retinitis remain limited, one can imagine treat- 
ment strategies that utilize systemic therapy to bring dis- 
ease under initial control, followed by combinations of 
systemic and local therapy to delay retinitis progression, 
and to protect the uninvolved eye and extraocular sites. 
Clinical trials aimed at developing such multimodality 
treatment strategies are underway and promise to 
advance the standard of care for CMV retinitis in patients 
with AIDS. 
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